The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically planning ...

Credit: Thinkstock. SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act ...

Levodopa is the gold standard for Parkinson's disease treatment, but not all patients find success with commonly prescribed tablets and pills. For those with limited motor control, a more sustainable ...

Indian clinical trial data for drugs like safinamide and apomorphine pump therapy are key for global pharma to seek US FDA approval. This along with specific therapies like gene based treatments ...

After successfully launching the D-mine Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include ...

If a patient with Parkinson’s disease fits into the “5-2-1” screening criteria– five times of oral tablet, stiffness for two hours and one hour of uncontrollable movements despite medication– laid ...

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

SALZBURG, Austria--(BUSINESS WIRE)--Launched as the D-mine ® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several European ...